ArticleJournal of feline medicine and surgery2026
Efficacy of combined grapiprant and tapentadol for analgesia in cats undergoing elective ovariohysterectomy.
Article in Journal of feline medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment.Pharmaceutics · 2026Article
- Pain and pain management in cats: an ever-evolving field.Journal of feline medicine and surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesThis study aimed to evaluate the effects of combined grapiprant and tapentadol on intraoperative physiological parameters, the occurrence of adverse events and postoperative analgesic efficacy in cats undergoing elective ovariohysterectomy, using two multidimensional pain scales.MethodsA total of 60 mixed-breed female cats were enrolled in a randomized, prospective, blinded study. The animals were evenly distributed into four groups (n = 15 per group). In total, 51 animals completed the study; the control group received placebo (CON; n = 11), while the grapiprant group (GRA; n = 13) received grapiprant (3.8 ± 0.5 mg/kg), the tapentadol group (TAP; n = 14) received tapentadol (5.3 ± 1.2 mg/kg) and the grapiprant-tapentadol group (GT; n = 13) received a combination of grapiprant (4.2 ± 0.5 mg/kg PO) and tapentadol (5 ± 0.6 mg/kg PO) 1 hour before initiation of the standardized anesthesia protocol and surgical procedure. Physiological parameters were monitored during surgery, and postoperative pain was assessed for 6 h after extubation using the Short Form of the UNESP-Botucatu Feline Pain Score (UFESP-SF) and the Feline Grimace Scale (FGS), administered by two blinded evaluators.ResultsNo adverse effects or statistically significant differences in physiological parameters were observed between groups. The assessment of pain scores showed good reliability, with intraclass correlation coefficient values of 0.89 for the FGS and 0.91 for the UFESP-SF, supporting inter-rater agreement for both instruments. At 3 h postoperatively, FGS scores differed significantly between the CON and GT groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.